Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Secondary non-Hodgkin's lymphomas]

P Cappelaere1

  • 1Centre Oscar-Lambert, Lille.

Bulletin Du Cancer
|September 30, 1998
PubMed
Summary
This summary is machine-generated.

Secondary non-Hodgkin's lymphoma (NHL) developing over a year after initial cancer treatment is rare. Its occurrence is linked to factors like prior Hodgkin's disease and immunodeficiency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The cured cancer patients].

Bulletin du cancer·2001
Same author

[Hippocrates' error].

Bulletin du cancer·2001
Same author

[Technology and humanism].

Bulletin du cancer·2001
Same author

[Hormonal replacement therapy and breast cancer].

Bulletin du cancer·1999
Same author

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Annals of oncology : official journal of the European Society for Medical Oncology·1998
Same author

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·1997
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
Same journal

[Robotics in oncological surgery].

Bulletin du cancer·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Epidemiology

Context:

  • Secondary non-Hodgkin's lymphoma (NHL) is an uncommon complication following treatment for a primary malignancy.
  • It is observed after chronic lymphatic leukemia or Hodgkin's disease, with a 20-year cumulative incidence of 3-5% post-Hodgkin's disease.
  • Secondary NHL appears less frequent after childhood cancers.

Purpose:

  • To describe the incidence, characteristics, and potential contributing factors of secondary NHL.
  • To differentiate secondary NHL from de novo NHL and NHL in immunosuppressed patients.

Summary:

  • Secondary NHL presents with extranodal sites, high-grade histology, B-phenotype, and advanced stage.
  • Prognosis for secondary NHL is comparable to de novo NHL when controlling for histology and stage.

Related Experiment Videos

  • Risk factors include patient age, prior lymphoproliferative disorders (especially Hodgkin's disease), and prior chemo-/radiotherapy; immunodeficiency is a key cofactor.

    • Impact:

    • Understanding secondary NHL aids in risk stratification and patient counseling.
    • Distinguishing secondary NHL from other lymphoma types is crucial for appropriate management.
    • Further research into the pathogenesis and specific risk factors can inform preventative strategies.